Two Lawsuits, One Organ Company

A law firm just announced it is investigating whether TransMedics directors breached their fiduciary duties to shareholders. The press release is from Halper Sadeh LLC, dated July 24. If you've been following TransMedics, this sounds like the same story you've been hearing for eighteen months. It isn't, exactly. It's a different kind of lawsuit, aimed at a different target, and it reveals something about how these things actually play out.

Let me start with the part that most people miss. There are two separate actions against TransMedics. The first, filed in January 2025, is a standard securities fraud class action: investors who bought the stock between February 2023 and January 2025 are suing for losses, alleging that TransMedics misled them about its business practices. That case is already past the motion to dismiss stage. On July 21, the court granted the complaint in part and denied it in part, and the case moved into discovery.

The Halper Sadeh investigation is different. It's a derivative suit inquiry - not investors suing for their own losses, but shareholders threatening to sue the board and officers on behalf of the company itself. The relief they're asking about includes corporate governance reforms, the return of funds to the company, and court-approved financial incentive awards. That language means the lawyers are looking at whether the insiders enriched themselves or mismanaged the company, and whether shareholders should be the ones getting money back through the corporate entity, not through direct damages. The structural difference matters because derivative suits require shareholder participation and court approval, and they tend to pressure boards more directly.

Now for the backstory, because you can't understand the lawsuits without knowing what detonated this.

On January 10, 2025, a short-seller called Scorpion Capital published a report describing TransMedics as the "most extreme and grotesque healthcare fraud" it had encountered in two decades of shorting. Scorpion alleged that TransMedics used kickbacks to medical providers to push its Organ Care System - a portable machine that keeps donor organs alive during transport - engaged in fraudulent billing, hid safety issues, steered damaged organs rejected by reputable surgeons to select transplant centers, and ran what they called an organ trafficking scheme. The report assigned TransMedics a target price of $0.

TransMedics denied everything. CEO Waleed Hassanein called the claims intended to "manipulate the market for financial gains", and the company engaged Kirkland & Ellis to explore legal options. The stock fell roughly 13% over two trading days. Within days, a half-dozen law firms - Rosen, Hagens Berman, Bragar Eagel, Robbins Geller, BFA, Kaplan Fox - were all announcing investigations.

The interesting part is what happened next. The stock recovered. By mid-year 2025, TransMedics was reporting $121.6 million in Q4 2024 revenue, up 50% year-over-year, with $35.5 million in full-year net income. Full-year 2025 revenue hit $605.5 million, up 37%. The company's Organ Care System, which replaces the old ice-transport method for organs going to transplant, continued to see surging adoption. In its 10-K, TransMedics disclosed convertible senior notes, a credit agreement with CIBC, and transplant aircraft and equipment on its balance sheet.

Then came Q1 2026. Revenue of $173.9 million. EPS of $0.30, versus the estimate of $0.61. Net income of $7.3 million, down from $25.7 million in the prior-year quarter. The stock fell more than 27% in one day. Analysts started asking whether the margin story was breaking.

That is the sequence of events. Scorpion report. Denial. Recovery. Earnings whiplash. And now, on top of the class action that's already in discovery, a derivative suit investigation that directly targets the board.

Here's the thing that makes this worth writing about. Scorpion Capital's report is not evidence. It's the product of a fund that makes money when the stock goes down. The firm's own website says it specializes in "intensive, differentiated research which uncovers what investors have missed and Wall Street is paid to ignore." That's the respectable phrasing for "we study companies we are short." The allegations may be true, partially true, or a pretext for market manipulation by the short side. That's genuinely not something I can adjudicate from a press release and a denial.

What I can adjudicate is the plumbing. What the class action complaint alleges, and what the court partially allowed to survive, is that TransMedics misrepresented that its business was driven by kickbacks, fraudulent overbilling, and coercive tactics, hid safety issues, and generally lacked safety oversight. The court didn't dismiss that. The case moved forward into discovery.

And now Halper Sadeh is asking whether the directors breached fiduciary duties. A fiduciary duty breach claim against a board is a serious step. It's the legal equivalent of saying: we don't just think the stock price went down because of bad news. We think the people running the company owed the shareholders a standard of care that they failed to meet. That could mean they approved the alleged practices, failed to oversee them, or didn't properly disclose known risks.

The market is already talking about this. TransMedics stock is at $81.55 today, up 6.6% on volume of 1.5 million shares. It's up roughly 10% over five days and 14% over twenty days, after being down 40% over 120 days. The 52-week high is $156. The 52-week low is $60. The stock is trying to decide what sort of company it actually is.

There's a lot of noise here. Law firms are advertising to investors. Short sellers are making accusations. TransMedics is booking revenue and planning its Q2 2026 earnings release, scheduled for August 4. The simplest model is this: the company sells a machine that keeps donor organs alive during transport. That's the business. The machine works, or it doesn't. Adoption is growing, or it isn't. The margins hold, or they don't.

But the legal overlay complicates all of that. Discovery in the class action means the company will have to produce internal documents, emails, financial records, and compliance materials. The derivative suit inquiry means the board is personally on the hook, not just the company. If either case finds that management knew about problematic practices and didn't disclose them, the consequences are structural, not just financial. Directors can be removed, governance can be overhauled, and the market can reprice the stock from "high-growth medtech" to "governance-discounted medtech." Those are very different valuations.

The weird part, and the point of the original Scorpion report, is the incentive layer sitting on top of the technology. If you're a company whose revenue depends on hospitals using your organ-preservation machines, and there are more hospitals using them than you'd expect from organic adoption, the question becomes: what else is driving demand? Kickbacks to providers, as Scorpion alleged, would make the growth look organic when it's actually purchased. That's the kind of thing that turns a growth story into a compliance problem, and a compliance problem into a securities fraud case.

TransMedics has 7,000+ transplants enabled by its technology, according to the company's own statements. That's not nothing. It's the sort of clinical outcome data that makes short reports look aggressive and company denials look credible. But the class action survived dismissal in part, which means the court found enough in the complaint to warrant discovery. And now there's a second legal track targeting the board itself.

The structural implication is clear. TransMedics is a company whose stock price depends on revenue growth that plaintiffs allege may have been fueled by practices the company didn't disclose. The court hasn't said the allegations are true. The court hasn't said they're false. The court said discovery happens. And meanwhile, a second set of lawyers is asking whether the board did its job.

Q2 earnings come out tomorrow, August 4. The market will care about the numbers. But the numbers now carry a legal premium or discount depending on what discovery turns up. That's not a timing call. That's the machine: a high-growth medical device company whose growth story is simultaneously being tested in court and being audited by its own shareholders, through a derivative suit inquiry that hasn't even formally been filed yet.

The basic point is that TransMedics is no longer just a story about whether its machines work. It's a story about whether the company's growth was earned or bought, whether the board oversaw the practices that generated that growth, and whether the market has been pricing the company as a clean growth name while two sets of lawyers are working through whether it qualifies for that label. The discovery phase in the class action, and the potential derivative suit, are the mechanism that will decide which version of the story the market uses going forward.